Sam Brusco, Associate Editor01.07.22
BD has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its BD Kiestra IdentifA system, which automates preparation of microbiology bacterial identification testing.
Using BD Synapsys informatics, BD Kiestra IdentifA lets lab technicians choose discrete bacterial colonies from a digital plate image. Robotics then pick up the selected organisms and prepare the sample for identification testing. Automating these typically cumbersome manual steps can help reduce potential for human error and produce more accurate diagnoses. Lab technicians can also focus their time on higher-value tasks as a result.
"BD continues to invest in automation and innovation for the microbiology laboratory to enable smart, connected, end-to-end workflows designed to accelerate insights and efficiency," Brooke Story, president of Integrated Diagnostic Solutions for BD told the press. "Our 'discovery to diagnostics' strategy positions us to provide best-in-class solutions at every point along this continuum."
According the company, Kiestra IdentifA is the sole FDA-cleared option available as part of a lab automation track-connected system to support specimen preparation for routine and challenging isolate types. BD’s Synapsys Informatics combined with Kiestra IdentifA and matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) mass spectrometry can help identify bacteria and yeass rapidly and accurately.
"The BD Kiestra IdentifA system transforms the manual workflow into one that is standardized, automated and digitized," said Greg Miziolek, vice president and general manager of the U.S. region for BD Integrated Diagnostic Solutions. "Mass spectrometry methods, including MALDI-ToF technology, have innovated and advanced microbial identification in clinical microbiology but often require a significant number of process steps and hands-on-time. The BD Kiestra IdentifA system uses automated colony picking and MALDI-ToF spotting to reduce time to pathogen identification, which in turn can help improve patient management."
Using BD Synapsys informatics, BD Kiestra IdentifA lets lab technicians choose discrete bacterial colonies from a digital plate image. Robotics then pick up the selected organisms and prepare the sample for identification testing. Automating these typically cumbersome manual steps can help reduce potential for human error and produce more accurate diagnoses. Lab technicians can also focus their time on higher-value tasks as a result.
"BD continues to invest in automation and innovation for the microbiology laboratory to enable smart, connected, end-to-end workflows designed to accelerate insights and efficiency," Brooke Story, president of Integrated Diagnostic Solutions for BD told the press. "Our 'discovery to diagnostics' strategy positions us to provide best-in-class solutions at every point along this continuum."
According the company, Kiestra IdentifA is the sole FDA-cleared option available as part of a lab automation track-connected system to support specimen preparation for routine and challenging isolate types. BD’s Synapsys Informatics combined with Kiestra IdentifA and matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) mass spectrometry can help identify bacteria and yeass rapidly and accurately.
"The BD Kiestra IdentifA system transforms the manual workflow into one that is standardized, automated and digitized," said Greg Miziolek, vice president and general manager of the U.S. region for BD Integrated Diagnostic Solutions. "Mass spectrometry methods, including MALDI-ToF technology, have innovated and advanced microbial identification in clinical microbiology but often require a significant number of process steps and hands-on-time. The BD Kiestra IdentifA system uses automated colony picking and MALDI-ToF spotting to reduce time to pathogen identification, which in turn can help improve patient management."